SYNCOM FORMU (I) LTD
SYNCOMF · General/Diversified · NSE
₹14
Current Market Price
Fair Value (DCF)
₹11
Margin of Safety
-20.2%
Updated 1d ago
YieldIQ Score
49/100
Piotroski F-Score
7/9
Economic Moat
Narrow
Confidence
50%
ROE
—
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹1,283 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.7%
Return on capital employed
EV / EBITDA
13.5×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
93.3×
EBIT covers interest
Current Ratio
4.55×
Short-term liquidity
Asset Turnover
1.11×
Revenue per ₹ of assets
Revenue CAGR (3Y)
28.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹13.65
Bear case
₹6.59
MoS -107.1%
Base case
₹10.89
MoS -25.3%
Bull case
₹13.66
MoS +0.1%
Ratio Trends
SYNCOMF · last 4 annual periods
ROE
14.4%
ROCE
20.6%
Operating Margin
—
Debt / Equity
0.01×
PE
65.5×
EV / EBITDA
18.6×
Historical Financials
SYNCOMF · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹218 Cr | ₹61.0 Cr | ₹74.6 Cr | ₹457 Cr | +28.1% |
| EBITDA | ₹32.0 Cr | ₹34.3 Cr | ₹43.0 Cr | ₹71.4 Cr | +30.7% |
| EBIT | — | ₹11.6 Cr | ₹11.2 Cr | — | -1.0% |
| PAT | ₹19.8 Cr | ₹8.5 Cr | ₹7.4 Cr | ₹49.4 Cr | +35.7% |
| EPS (diluted) | — | ₹0.10 | ₹0.10 | — | +0.0% |
| CFO | ₹16.3 Cr | ₹10.5 Cr | ₹-6.0 Cr | ₹23.4 Cr | +12.8% |
| CapEx | ₹-11.3 Cr | — | — | ₹-10.0 Cr | — |
| FCF | ₹5.0 Cr | — | — | ₹13.5 Cr | +39.0% |
| Total Assets | ₹308 Cr | ₹378 Cr | ₹405 Cr | ₹413 Cr | +10.3% |
| Total Debt | ₹57.8 Cr | ₹83.2 Cr | ₹72.5 Cr | ₹4.6 Cr | -57.0% |
| Shareholders' Equity | ₹222 Cr | ₹256 Cr | ₹288 Cr | ₹342 Cr | +15.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SYNCOMF vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| SAKAR SAKAR | — | — | Pending | 6.1% | — |
| BETA BETA | — | — | Pending | 21.5% | — |
| VENUSREM VENUSREM | — | — | Pending | 8.1% | — |
| JAGSNPHARM JAGSONPAL PHARMACEUTICALS | -6.1% | 61 | Fairly valued | 23.1% | — |
| BAJAJHCARE BAJAJHCARE | — | — | Pending | 8.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SYNCOMF in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SYNCOMF →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SYNCOMF →
Compare
Head-to-head with peers
Compare SYNCOMF side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SYNCOMFNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.